{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:45Z","timestamp":1772165745745,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid malignancies are among the most common endocrine cancers worldwide. Owing to the angiogenic nature of these malignancies, tyrosine kinase inhibitors (TKIs) are an attractive potential treatment. However, TKIs have been associated with an increased risk of tumor cavitation, in turn linked to poor outcomes, in patients with malignancies in the lungs, where thyroid cancer commonly metastasizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We performe d a retrospective cohort study of patients with thyroid cancer and evidence of metastatic disease to the lung that were treated with multi-targeted antiangiogenic TKIs. The primary objective of this study was to determine the incidence of pulmonary cavitation. The secondary objective was to evaluate the effect of pulmonary cavitation on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 83 patients with pulmonary nodules, 10 developed cavitation during treatment. Of these 83 patients, two patients had to stop the treatment due to pneumothorax. Additionally, cavitation did not demonstrate any significant effect on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with thyroid cancer and evidence of metastatic disease to the chest, the use of multi-targeted TKIs led to cavitations that were not uncommon but clinical consequences were marginal. Treatment was stopped only in two patients that developed pneumothorax, however the small sample is a strong limitation of our study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07693-5","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T07:03:16Z","timestamp":1606892596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents"],"prefix":"10.1186","volume":"20","author":[{"given":"Saumil","family":"Datar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Dadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-4268","authenticated-orcid":false,"given":"Horiana B.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"7693_CR1","first-page":"30","volume":"8","author":"QT Nguyen","year":"2015","unstructured":"Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8:30\u201340.","journal-title":"Am Health Drug Benefits"},{"key":"7693_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2007.01.002","volume":"62","author":"S Sun","year":"2007","unstructured":"Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol. 2007;62:93\u2013104.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7693_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1089\/105072502320908286","volume":"12","author":"AJ Bauer","year":"2002","unstructured":"Bauer AJ, Terrell R, Doniparthi NK, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid. 2002;12:953\u201361.","journal-title":"Thyroid"},{"key":"7693_CR4","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/cncr.29395","volume":"121","author":"ME Cabanillas","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121:2749\u201356.","journal-title":"Cancer"},{"key":"7693_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/14656566.2016.1206078","volume":"17","author":"J Krajewska","year":"2016","unstructured":"Krajewska J, Kukulska A, Jarzab B. Efficacy of lenvatinib in treating thyroid cancer. Expert Opin Pharmacother. 2016;17:1683\u201391.","journal-title":"Expert Opin Pharmacother"},{"key":"7693_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"7693_CR7","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.3390\/ijms16036153","volume":"16","author":"P Fallahi","year":"2015","unstructured":"Fallahi P, Mazzi V, Vita R, et al. New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 2015;16:6153\u201382.","journal-title":"Int J Mol Sci"},{"key":"7693_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1089\/thy.2018.0060","volume":"28","author":"ME Cabanillas","year":"2018","unstructured":"Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid. 2018;28:945\u201351.","journal-title":"Thyroid"},{"key":"7693_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JTO.0b013e318168c7e9","volume":"3","author":"EM Marom","year":"2008","unstructured":"Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol. 2008;3:351\u20137.","journal-title":"J Thorac Oncol"},{"key":"7693_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","volume":"27","author":"SJ Crabb","year":"2009","unstructured":"Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009;27:404\u201310.","journal-title":"J Clin Oncol"},{"key":"7693_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1102\/1470-7330.2012.0027","volume":"12","author":"M Nishino","year":"2012","unstructured":"Nishino M, Cryer SK, Okajima Y, et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012;12:225\u201335.","journal-title":"Cancer Imaging"},{"key":"7693_CR12","first-page":"277","volume":"85","author":"GD Dodd","year":"1961","unstructured":"Dodd GD, Boyle JJ. Excavating pulmonary metastases. Am J Roentgenol Radium Therapy, Nucl Med. 1961;85:277\u201393.","journal-title":"Am J Roentgenol Radium Therapy, Nucl Med"},{"key":"7693_CR13","first-page":"66","volume":"50","author":"LS Kolodziejski","year":"2003","unstructured":"Kolodziejski LS, Dyczek S, Duda K, Goralczyk J, Wysocki WM, Lobaziewicz W. Cavitated tumor as a clinical subentity in squamous cell lung cancer patients. Neoplasma. 2003;50:66\u201373.","journal-title":"Neoplasma"},{"key":"7693_CR14","first-page":"154","volume":"4","author":"H Miura","year":"1998","unstructured":"Miura H, Taira O, Hiraguri S, Hagiwara M, Kato H. Cavitating adenocarcinoma of the lung. Ann Thorac Cardiovasc Surg. 1998;4:154\u20138.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"7693_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/107327480601300206","volume":"13","author":"KN Patel","year":"2006","unstructured":"Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13:119\u201328.","journal-title":"Cancer Control"},{"key":"7693_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134\u201341.","journal-title":"J Clin Oncol"},{"key":"7693_CR17","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639\u201346.","journal-title":"J Clin Oncol"},{"key":"7693_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jpedsurg.2015.01.005","volume":"50","author":"RB Interiano","year":"2015","unstructured":"Interiano RB, McCarville MB, Wu J, Davidoff AM, Sandoval J, Navid F. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory\/recurrent solid tumors. J Pediatr Surg. 2015;50:1484\u20139.","journal-title":"J Pediatr Surg"},{"key":"7693_CR19","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07693-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T23:44:37Z","timestamp":1606952677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07693-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7693"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07693-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.20512\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.20512\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.20512\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"3 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Texas MD Anderson Cancer Center Institutional Review Board approved this study and informed consent was waived by the Institutional Review Board 4 with the protocol number PA17\u20130760.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1181"}}